Skip to main content
Premium Trial:

Request an Annual Quote

ABI Shares Slide 5.5 Percent After Bank Downgrades Stock; Lackluster Organic Revenue Growth Cited

NEW YORK, May 24 (GenomeWeb News) - Shares in Applied Biosystems were down 5.48 percent, or $1.24, at $21.37 in late-afternoon trading today after an investment bank downgraded the stock.

 

UBS downgraded the stock to 'Reduce' from 'Neutral' this morning. The bank said that "given lackluster organic revenue growth, increasing competition, and our view that transforming M&A choices may be limited, we do not believe ABI shares should trade at a premium to the group multiple at this time," according to a Reuters report.

 

UBS stressed that ABI "remains an important brand name in the life sciences sector."

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.